

#6

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 040283/0183	SERIAL NO. 09/622,544
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Sarkis Barret KALINDJIAN et al.	FILING DATE 10/13/2000
		GROUP ART UNIT 1624 Unassigned	

APR 12 2001
U.S. PATENT & TRADEMARK OFFICE

RECEIVED
APR 16 2001
TECH CENTER 160002900

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
B.K.	A1	5,281,625	01/94	Zipplies et al	514	634	


FOREIGN PATENT DOCUMENTS								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
B.K.	A2	390 925	04/65	Switzerland				No
	A3	390 926	04/65	Switzerland				No
	A4	390 927	04/65	Switzerland				No
	A5	390 928	04/65	Switzerland				No
	A6	342 957	12/59	Switzerland				No
	A7	345 893	04/60	Switzerland				No
	A8	346 879	06/60	Switzerland				No
	A9	362 079	05/62	Switzerland				No
	A10	393 337	06/65	Switzerland				No
	A11	442 298	08/67	Switzerland				No
	A12	1,352,161	05/64	France				No
	A13	952,194	12/61	London				
	A14	1,185,080	03/70	London				
	A15	42-21010	10/67	Japan				Abst.
	A16	0 525 203	02/93	Europe				
	A17	0 199 845	11/86	Europe				
	A18	92/15567	09/92	WIPO				
	A19	97/29092	08/97	WIPO				
	A20	93/14070	07/93	WIPO				
B.K.	A21	97/45108	12/97	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
D.K.	A22	Ganellin et al., "Synthesis of Potent Non-imidazole Histamine H ₃ -Receptor Antagonists", Arch. Pharm. Pharm. Med. Chem., 331:389-394, (1998), Wiley-VCH Verlag GmbH

EXAMINER <i>Bruno K. J.</i>	DATE CONSIDERED 11/14/01
--------------------------------	-----------------------------

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 040283/0183	SERIAL NO. 09/622,544
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Sarkis Barret KALINDJIAN et al.	
		FILING DATE 10/13/2000	GROUP ART UNIT 1624 Unassigned



U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

D.K.	A23	Decicco et al., "Amide Surrogates of Matrix Metalloproteinase inhibitors: urea and sulfonamide mimics", Bioorganic & Medicinal Chemistry Letters, vol. 7, no. 8, pp. 2331-2336, 1997, The DuPont Merck Pharm. Co.
	A24	MacPherson et al., "Discovery of CGS 27023A, a Non-Peptide, potent, and orally active stromelysin inhibitor That blocks cartilage degradation in rabbits", J. Med. Chem., 40:2525-2532, 1997, American Chemical Society
	A25	Wolin et al., "Novel H ₃ receptor antagonists. Sulfonamide homologs of histamine", Bioorganic & Medicinal Chemistry letters 8 (1998) pp.2157-2162, Elsevier Science Ltd.
	A26	Vollinga et al., "Homologs of Histamine as histamine H ₃ receptor antagonists: a new potent and selective H ₃ Antagonist, 4(5)-(5-Aminopentyl)-1H-imidazole", J. Med. Chem. 1995, 38:266-271, American Chem. Soc.
	A27	Timmerman, "Histamine H ₃ ligands: just pharmacological tools or potential therapeutic agents?", J. Med. Chem., 1990, 33:4-11, American Chemical Society
	A28	Stürzebecher et al., "Synthesis and structure-activity relationship of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine", J. Med. Chem., 1997, 40:3091-3099, Pentapharm Ltd.
	A29	Young et al., "Development of a new physicochemical model for brain penetration and its application to the Design of centrally acting H ₂ receptor histamine antagonist", J. Med. Chem. 1988, 31:656-671, Smith Kline & French Research Ltd.
	A30	Vollinga, "New ligands of the histamine H ₃ receptor", Synthesis, Structure activity relationships and molecular Pharmacology, pp: 7-210, 1995, Leiden/Amsterdam center for drug research
B.K.		

EXAMINER <i>Bruce K/M</i>	DATE CONSIDERED 11/14/01
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.	